ArticleBMC women's health2023
Time trend of global uterine cancer burden: an age-period-cohort analysis from 1990 to 2019 and predictions in a 25-year period.
Article in BMC women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of oral contraceptives and risk of endometrial cancer: A systematic review and meta-analysis.Acta obstetricia et gynecologica Scandinavica · 2025Pooled it
- Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines.Journal of gynecologic oncology · 2025Guideline
- Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.Journal of gynecologic oncology · 2025Trial
- Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.Journal of gynecologic oncology · 2024Trial
- Article
- Pesticide Exposure and Gynecological Cancers: A Review of Epidemiological Evidence and Mechanistic Pathways.Diseases (Basel, Switzerland) · 2026Review
- A Retrospective Cohort Study of Uterine Cancer Epidemiological Analysis and Age-Based Disparities in Saudi Arabian Population across 32 Years.Saudi medical journal · 2026Article
- Endometrial cancer awareness as a public health blind spot: a cross-sectional survey study.BMC public health · 2026Article
- Exploring Women's Experiences of Information Across Their Endometrial Cancer Diagnosis and Treatment: A Qualitative Analysis.Psycho-oncology · 2026Article
- Quantitative analysis of trends and inequalities in disease burden and care quality of gynecological cancers, 1990-2021.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- Is the incidence of early-onset cancers increasing in the northeast of Italy? A 30-year analysis of the regional cancer registration data by age, 1987-2019.International journal of cancer · 2026Observational
- Article
- Mortality burden of malignant neoplasms of the corpus uteri in Mexico: an analysis of trends from 2000 to 2022.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2026Article
- Recommendations for the treatment of endometrial cancer in settings with limited resources: report from the International Gynecological Cancer Society consensus meeting.Frontiers in oncology · 2026Article
- SAMD4B: a novel prognostic biomarker of endometrial carcinoma.Translational cancer research · 2025Article
- Assessment of the PD-1/PD-L1/PD-L2 Immune Checkpoints Pathway in Endometrial Cancer and Its Clinical Significance.Cancers · 2025Article
- Machine Learning-Predictive Models for Survival in Uterine Cancer Patients With Type 2 Diabetes: A Territory-Wide Cohort Study.The journal of obstetrics and gynaecology research · 2025Article
- Long-term outcomes of fertility-sparing treatment in endometrial carcinoma and endometrial intraepithelial neoplasia: Recurrence risk factors over a 9-year follow-up.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Understanding Contemporary Endometrial Cancer Survivorship Issues: Umbrella Review and Healthcare Professional Survey.Cancers · 2025Review
- Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUterine cancer remains a serious medical problem worldwide. This study aimed to explore the global time trends of uterine cancer burden using the age-period-cohort model and forecast incidence to 2044.
methodsData were downloaded from the Global Burden of Disease 2019. The age-period-cohort model was used to estimate age, period and birth cohort effects. We also predict uterine cancer incidence to 2044.
resultsGlobally, there were 435,041 incident cases (95% UI: 245,710 to 272,470) and 91,640 deaths of uterine cancer (95% UI: 39,910 to 44,140) in 2019. During the past 30 years, the age-standardized incidence and death rates increased by 15.3% and decreased by 21.6%, respectively. Between 1990 and 2019, the high-sociodemographic index region had the highest overall annual percentage changes. The age effect showed the uterine cancer incidence rate first increased and then decreased with age. The period and cohort relative rate ratio showed upward trends during the study period. Incident cases of uterine cancer may increase to more than six hundred thousand in 2044.
conclusionUterine cancer causes a high disease burden in high-income regions and the global incidence may continue to increase in the future. Improving awareness of risk factors and reducing the proportion of the obese population are necessary to reduce future burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.